Volitionrx Company Insiders
VNRX Stock | USD 0.70 0.01 1.45% |
Volitionrx employs about 101 people. The company is managed by 17 executives with a total tenure of roughly 29 years, averaging almost 1.0 years of service per executive, having 5.94 employees per reported executive. Break down of Volitionrx's management performance can provide insight into the company performance.
Martin Faulkes Chairman Executive Chairman |
Volitionrx |
Volitionrx Management Team Effectiveness
The company has return on total asset (ROA) of (1.0082) % which means that it has lost $1.0082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.3006) %, meaning that it created substantial loss on money invested by shareholders. Volitionrx's management efficiency ratios could be used to measure how well Volitionrx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Volitionrx's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 4.75 in 2024, whereas Return On Tangible Assets are likely to drop (1.33) in 2024. At this time, Volitionrx's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 22.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.8 M in 2024.Common Stock Shares Outstanding is likely to rise to about 74.8 M in 2024, despite the fact that Net Loss is likely to grow to (26.2 M).
Volitionrx Workforce Comparison
Volitionrx is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 971. Volitionrx retains roughly 101 in number of employees claiming about 10% of equities under Health Care industry.
Volitionrx Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Volitionrx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Volitionrx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Volitionrx insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Still Timothy I over two weeks ago Insider Trading | ||
Jacob Micallef over a month ago Disposition of 5200 shares by Jacob Micallef of Volitionrx at 0.883 subject to Rule 16b-3 | ||
Rubin Ethel over a month ago Insider Trading | ||
Innes Guy Archibald over two months ago Acquisition by Innes Guy Archibald of 400000 shares of Volitionrx subject to Rule 16b-3 | ||
Forterre Gael over two months ago Acquisition by Forterre Gael of 10240 shares of Volitionrx subject to Rule 16b-3 | ||
Kway Jasmine over two months ago Acquisition by Kway Jasmine of 16750 shares of Volitionrx subject to Rule 16b-3 | ||
Nguyen Kim over two months ago Acquisition by Nguyen Kim of 9171 shares of Volitionrx subject to Rule 16b-3 | ||
Innes Guy Archibald over three months ago Acquisition by Innes Guy Archibald of 150000 shares of Volitionrx at 0.67 subject to Rule 16b-3 |
Volitionrx Notable Stakeholders
A Volitionrx stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Volitionrx often face trade-offs trying to please all of them. Volitionrx's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Volitionrx's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Martin Faulkes | Executive Chairman | Profile | |
Thomas Bygott | Sales Director | Profile | |
Salvatore DVM | Chief LLC | Profile | |
Scott Powell | Executive Relations | Profile | |
Gael MBA | Chief Officer | Profile | |
Gaetan Michel | Chief Officer | Profile | |
Louise Day | Chief Officer | Profile | |
Jacob MBA | Chief Officer | Profile | |
Mark MBA | Chief Officer | Profile | |
Cameron MBA | Group Founder | Profile | |
Terig Hughes | Group Treasurer | Profile | |
Jacob Micallef | Chief Scientific Officer | Profile | |
Salvatore Butera | Chief LLC | Profile | |
Andrew MBBS | Chief Officer | Profile | |
Rodney LLB | Corporate Secretary | Profile | |
Sharon Ballesteros | U Process | Profile | |
Nicholas Plummer | Group Counsel | Profile |
About Volitionrx Management Performance
The success or failure of an entity such as Volitionrx often depends on how effective the management is. Volitionrx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Volitionrx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Volitionrx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.26) | (1.33) | |
Return On Capital Employed | 9.26 | 9.72 | |
Return On Assets | (1.26) | (1.33) | |
Return On Equity | 4.53 | 4.75 |
Please note, the imprecision that can be found in Volitionrx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Volitionrx. Check Volitionrx's Beneish M Score to see the likelihood of Volitionrx's management manipulating its earnings.
Volitionrx Workforce Analysis
Traditionally, organizations such as Volitionrx use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Volitionrx within its industry.Volitionrx Manpower Efficiency
Return on Volitionrx Manpower
Revenue Per Employee | 7.7K | |
Revenue Per Executive | 45.6K | |
Net Loss Per Employee | 349.7K | |
Net Loss Per Executive | 2.1M |
Additional Tools for Volitionrx Stock Analysis
When running Volitionrx's price analysis, check to measure Volitionrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Volitionrx is operating at the current time. Most of Volitionrx's value examination focuses on studying past and present price action to predict the probability of Volitionrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Volitionrx's price. Additionally, you may evaluate how the addition of Volitionrx to your portfolios can decrease your overall portfolio volatility.